Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nane C. Kuznik
Institution:
Karlsruhe Institute of Technology
Observed institution:
Karlsruhe Institute of Technology
ORCID:
0009-0005-2243-9705
Observed ORCID:
0009-0005-2243-9705
OpenAlex ID:
A5048547543
Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer
2021
·
Nane C. Kuznik
, Valeria Solozobova
, et al.
·
ACS Chemical Biology
·
16
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
·
Cancer Research Communications
·
12
PDF
Figure S1 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Data from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 6 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 7 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Supplementary Data from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S3 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 3 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S4 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 4 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 8 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 5 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 6 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S6 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S5 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S5 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 1 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Supplementary Data from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S3 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
FIGURE 1 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Figure S4 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023
·
Mengwu Pan
, Valeria Solozobova
, et al.
Show more works
View as search
Works count:
48
Citation count:
28
H-index:
2
I10-index:
2
Year
Topic
Type